These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 7769903

  • 21. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

  • 22. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.
    Choi JH, Lee BH, Ko JM, Sohn YB, Lee JS, Kim GH, Heo SH, Park JY, Kim YM, Kim JH, Yoo HW.
    J Korean Med Sci; 2015 Apr; 30(4):378-84. PubMed ID: 25829804
    [Abstract] [Full Text] [Related]

  • 23. [Current treatment for Gaucher's disease and new prospects].
    Giraldo P, Latre P.
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():50-4. PubMed ID: 22230127
    [Abstract] [Full Text] [Related]

  • 24. [Therapeutic targets in Gaucher's disease].
    Giraldo P, Roca M.
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():46-9. PubMed ID: 22230126
    [Abstract] [Full Text] [Related]

  • 25. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease.
    Mistry PK, Wraight EP, Cox TM.
    Lancet; 1996 Dec 07; 348(9041):1555-9. PubMed ID: 8950883
    [Abstract] [Full Text] [Related]

  • 26. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A.
    Blood Cells Mol Dis; 2014 Dec 07; 53(4):253-60. PubMed ID: 24950666
    [Abstract] [Full Text] [Related]

  • 27. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul 07; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 28. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE.
    N Engl J Med; 1991 May 23; 324(21):1464-70. PubMed ID: 2023606
    [Abstract] [Full Text] [Related]

  • 29. Glucocerebrosidase for treatment of Gaucher's disease: first German long-term results.
    Niederau C, Holderer A, Heintges T, Strohmeyer G.
    J Hepatol; 1994 Oct 23; 21(4):610-7. PubMed ID: 7814809
    [Abstract] [Full Text] [Related]

  • 30. Treatment regimens in Gaucher's disease.
    Beutler E.
    Lancet; 1995 Aug 26; 346(8974):581-2. PubMed ID: 7658807
    [No Abstract] [Full Text] [Related]

  • 31. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
    Mazher W, Ali J, Abubakar S, Basar S, Murtaza G.
    J Ayub Med Coll Abbottabad; 2018 Aug 26; 30(3):479-481. PubMed ID: 30465391
    [Abstract] [Full Text] [Related]

  • 32. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 26; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 33. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A.
    Blood Cells Mol Dis; 2012 Jan 15; 48(1):45-50. PubMed ID: 22047948
    [Abstract] [Full Text] [Related]

  • 34. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
    Latre P, Giraldo P.
    Med Clin (Barc); 2011 Sep 15; 137 Suppl 1():39-42. PubMed ID: 22230124
    [Abstract] [Full Text] [Related]

  • 35. Low-dose versus high-frequency regimens in Gaucher's disease.
    Maródi L.
    Lancet; 1995 Nov 25; 346(8987):1434. PubMed ID: 7475855
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease.
    Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, Agosti E.
    Lancet; 1994 Dec 17; 344(8938):1679-82. PubMed ID: 7996964
    [Abstract] [Full Text] [Related]

  • 39. [Enzyme replacement therapy: a new treatment concept in Gaucher disease].
    Beck M, Mengel E, Barone R.
    Wien Klin Wochenschr; 1997 Feb 14; 109(3):81-5. PubMed ID: 9139464
    [Abstract] [Full Text] [Related]

  • 40. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, Puri RD, Gupta N, Kishnani PS, Mistry PK.
    Indian Pediatr; 2011 Oct 14; 48(10):779-84. PubMed ID: 22080680
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.